Oracea (Doxycycline)

Doxycycline, the active ingredient in Oracea, is a tetracycline antibiotic presented as a tablet for oral use. It treats rosacea in adults by reducing inflammation and lesions.

GNH USA supplies Oracea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oracea (doxycycline) is used in the management of inflammatory skin conditions, particularly rosacea.

- Rosacea (papulopustular): reduces inflammatory papules and pustules. - Rosacea (erythematotelangiectatic): improves persistent facial redness. - Rosacea (overall): decreases severity and frequency of flare‑ups.

Adverse reactions may occur with oral doxycycline therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Photosensitivity: increased risk of sunburn. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): difficulty breathing, swelling. - Stevens‑Johnson syndrome: severe skin blistering. - Clostridioides difficile‑associated colitis: severe diarrhea with fever.

Use Oracea with attention to specific safety considerations.

- Pregnancy: risk unknown; avoid unless clearly needed. - Breastfeeding: risk unknown; consider alternative therapy. - Renal impairment: dose adjustment may be required. - Sun exposure: avoid excessive UV, use sunscreen and protective clothing. - Drug interactions: review concomitant medications for potential interactions. - Store below 25°C: keep in the original pack, protect from moisture.

Doxycycline may interact with several medicines; monitor accordingly.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce doxycycline absorption. - Isotretinoin: increased risk of intracranial hypertension. - Warfarin: enhanced anticoagulant effect, may increase INR.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce efficacy, consider backup method. - Cyclosporine: potential increase in nephrotoxicity. - Retinoids: additive photosensitivity risk.